Ampliphi Biosciences Corp.

Founded in 1986, NeoMPS provides a full range of products and services in the field of customized peptide synthesis for research and development, amino acids and peptide building blocks. The company has expertise in the area of manufacturing peptides and provides antipeptide antibodies. The company has a facility in France and has obtained the French Health Products Safety Agency certification. The company specializes in developing peptide derivatives and supplies a high quantity of active pharmaceutical ingredients to biopharmaceutical companies worldwide. It participates in various science exhibitions and conferences. It has a staff of trained professionals who specialize in scientific research. The company s Web site provides product catalog download options. It has a branch in San Diego

Targacept is a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat diseases and disorders of the central nervous system. It is a leader in the field of neuronal nicotinic acetylcholine receptor chemistry and biology. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. Targacept s product candidates are designed to selectively target specific NNR subtypes and promote therapeutic effects and limit adverse side effects. Targacept has product candidates in clinical development for cognitive impairment, including Alzheimer s disease and age-associated memory impairment, pain and depression. From 1997 to 2000, Targacept was a subsidiary of R. J. Reynolds Tobacco Company. During this time, the company s investigations into the biological effects of nicotine suggested a role for NNRs in the treatment of human disease and led to the creation of Targacept.